India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further.
作者信息
Udwadia Zarir F, Furin Jennifer
机构信息
Department of Pulmonary Medicine, P. D. Hinduja Hospital, Mumbai, Maharashtra, India.
Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
出版信息
Lung India. 2021 Nov-Dec;38(6):590-591. doi: 10.4103/lungindia.lungindia_425_21.
Abstract
摘要
相似文献
1
India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further.印度应加快获取以贝达喹啉为基础的全口服治疗方案，而不是进一步拖延。
Lung India. 2021 Nov-Dec;38(6):590-591. doi: 10.4103/lungindia.lungindia_425_21.
2
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.亚美尼亚、印度和南非采用贝达喹啉与德拉马尼联合治疗耐多药结核病患者的早期安全性和疗效：一项回顾性队列研究。
Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13.
3
Strengthened capacity of India´s bedaquiline Conditional Access Programme for introducing new drugs and regimens.增强印度巴德昔利醇有条件准入方案的能力，以推出新的药物和方案。
Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1067-1072. doi: 10.5588/ijtld.20.0136.
4
Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.在部分高负担国家中，贝达喹啉治疗耐多药结核病的健康结局。
BMC Health Serv Res. 2017 Jan 26;17(1):87. doi: 10.1186/s12913-016-1931-3.
5
Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China.采用包含贝达喹啉的方案对中国耐多药结核病负担的长期影响。
BMC Infect Dis. 2020 Feb 10;20(1):113. doi: 10.1186/s12879-020-4795-4.
6
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.贝达喹啉对南非耐多药结核病患者死亡率的影响：一项回顾性队列研究。
Lancet Respir Med. 2018 Sep;6(9):699-706. doi: 10.1016/S2213-2600(18)30235-2. Epub 2018 Jul 11.
7
Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection.长效注射贝达喹啉制剂在潜伏性结核感染小鼠模型中的活性。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.00007-19. Print 2019 Apr.
8
Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis.含贝达喹啉和不含贝达喹啉的全口服短程方案治疗耐多药结核病的培养转阴率无显著差异。
Int J Infect Dis. 2021 Oct;111:138-147. doi: 10.1016/j.ijid.2021.08.055. Epub 2021 Aug 25.
9
Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.贝达喹啉与含注射剂的耐多药结核病治疗方案：成本效益分析。
Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):677-689. doi: 10.1080/14737167.2018.1507821. Epub 2018 Aug 23.
10
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.《endTB 观察性研究方案：贝达喹啉或含德拉马尼方案治疗耐多药结核病》。
BMC Infect Dis. 2019 Aug 20;19(1):733. doi: 10.1186/s12879-019-4378-4.
引用本文的文献
1
Reply: Roll out of bedaquiline without drug susceptibility testing leads to emergence of bedaquiline-resistance in high burden countries with tuberculosis - Danger of losing a novel drug.回复：在未进行药敏试验的情况下推广使用贝达喹啉会导致结核病高负担国家出现贝达喹啉耐药性——失去一种新药的风险。
Lung India. 2022 Jul-Aug;39(4):389-390. doi: 10.4103/lungindia.lungindia_31_22.
本文引用的文献
1
WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?《世界卫生组织2020年结核病综合指南：迈向全口服治疗方案》：各国应匆忙行动吗？
Lung India. 2021 Jul-Aug;38(4):303-306. doi: 10.4103/lungindia.lungindia_982_20.
2
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings.全口服长程方案在高负担环境下对耐多药结核病的管理是有效的。
Eur Respir J. 2022 Jan 20;59(1). doi: 10.1183/13993003.04345-2020. Print 2022 Jan.
3
Challenging drug-resistant TB treatment journey for children, adolescents and their care-givers: A qualitative study.儿童、青少年及其照顾者耐药结核病治疗之旅充满挑战：一项定性研究。
PLoS One. 2021 Mar 10;16(3):e0248408. doi: 10.1371/journal.pone.0248408. eCollection 2021.
4
Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic.在孟买的一家大型私人诊所，很少有符合新推荐的短程耐多药结核病方案条件的人。
BMC Infect Dis. 2019 Jan 28;19(1):94. doi: 10.1186/s12879-019-3726-8.
5
The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?已知之恶：使用注射剂治疗耐多药结核病是否合理？
Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1114-1126. doi: 10.5588/ijtld.17.0468.
Zotero 插件